Current biomarkers and treatment strategies in Alzheimer disease: An overview and future perspectives

Bhole, Ritesh P.; Chikhale, Rupesh V.; Rathi, Karishma M.

doi:10.1016/j.ibneur.2023.11.003

Cited by 10 publications

(2 citation statements)

References 358 publications

(552 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Modern approaches involve the further modification of their structure directed to a higher efficiency in binding AChE and lowering the side effects. A summary of current directions in the design of drugs with the AChE inhibitory action can be found in a review [52].…”

Section: Anticholinesterase Drugsmentioning

confidence: 99%

Electrochemical Acetylcholinesterase Sensors for Anti-Alzheimer’s Disease Drug Determination

Ivanov,

Shamagsumova,

Larina

et al. 2024

Biosensors

View full text Add to dashboard Cite

Neurodegenerative diseases and Alzheimer’s disease (AD), as one of the most common causes of dementia, result in progressive losses of cholinergic neurons and a reduction in the presynaptic markers of the cholinergic system. These consequences can be compensated by the inhibition of acetylcholinesterase (AChE) followed by a decrease in the rate of acetylcholine hydrolysis. For this reason, anticholinesterase drugs with reversible inhibition effects are applied for the administration of neurodegenerative diseases. Their overdosage, variation in efficiency and recommendation of an individual daily dose require simple and reliable measurement devices capable of the assessment of the drug concentration in biological fluids and medications. In this review, the performance of electrochemical biosensors utilizing immobilized cholinesterases is considered to show their advantages and drawbacks in the determination of anticholinesterase drugs. In addition, common drugs applied in treating neurodegenerative diseases are briefly characterized. The immobilization of enzymes, nature of the signal recorded and its dependence on the transducer modification are considered and the analytical characteristics of appropriate biosensors are summarized for donepezil, huperzine A, rivastigmine, eserine and galantamine as common anti-dementia drugs. Finally, the prospects for the application of AChE-based biosensors in clinical practice are discussed.

show abstract

Section: Anticholinesterase Drugsmentioning

confidence: 99%

Electrochemical Acetylcholinesterase Sensors for Anti-Alzheimer’s Disease Drug Determination

Ivanov,

Shamagsumova,

Larina

et al. 2024

Biosensors

View full text Add to dashboard Cite

show abstract

“…Alzheimer’s disease (AD) is a neurodegenerative disease, classified based on its progressive decline and loss of neurons (Tom SE et al 2015 ). As one of the main causes of dementia, AD has two categories, namely early-onset or sporadic AD that occurs after the age of 65, and familial AD that contains autosomal dominant missense mutations (Bhole RP et al 2024 ). In particular, dysfunction of the dorsolateral prefrontal cortex is associated with impaired executive control function and working memory (Hertrich I et al 2021 ; Kumar S et al 2017 ) The AD pathology primarily involves misfolded, oligomerised amyloid β (Aβ) plaques (Grundke-Iqbal I et al 1986 ) and accumulated neurofibrillary tangles (NFTs) (Glenner GG and Wong CW 1984 ), which are assessed for in AD pathology progression (Braak CD, E. Braak and F. Piette 1992 ).…”

Section: Introductionmentioning

confidence: 99%

Investigation of the Circular Transcriptome in Alzheimer’s Disease Brain

Gao,

Xu,

Cheng

et al. 2024

J Mol Neurosci

View full text Add to dashboard Cite

Circular RNAs (circRNAs) are a subclass of non-coding RNAs which have demonstrated potential as biomarkers for Alzheimer’s disease (AD). In this study, we conducted a comprehensive exploration of the circRNA transcriptome within AD brain tissues. Specifically, we assessed circRNA expression patterns in the dorsolateral prefrontal cortex collected from nine AD-afflicted individuals and eight healthy controls. Utilising two circRNA detection tools, CIRI2 and CIRCexplorer2, we detected thousands of circRNAs and performed a differential expression analysis. CircRNAs which exhibited statistically significantly differential expression were identified as AD-specific differentially expressed circRNAs. Notably, our investigation revealed 120 circRNAs with significant upregulation and 1325 circRNAs displaying significant downregulation in AD brains when compared to healthy brain tissue. Additionally, we explored the expression profiles of the linear RNA counterparts corresponding to differentially expressed circRNAs in AD-afflicted brains and discovered that the linear RNA counterparts exhibited no significant changes in the levels of expression. We used CRAFT tool to predict that circUBE4B had potential to target miRNA named as hsa-miR-325-5p, ultimately regulated CD44 gene. This study provides a comprehensive overview of differentially expressed circRNAs in the context of AD brains, underscoring their potential as molecular biomarkers for AD. These findings significantly enhance our comprehension of AD’s underlying pathophysiological mechanisms, offering promising avenues for future diagnostic and therapeutic developments.

show abstract

Macrophage migration inhibitor factor (MIF): Potential role in cognitive impairment disorders

Zeng,

Hu,

Zhang

et al. 2024

Cytokine & Growth Factor Reviews

View full text Add to dashboard Cite

Current biomarkers and treatment strategies in Alzheimer disease: An overview and future perspectives

Cited by 10 publications

References 358 publications

Electrochemical Acetylcholinesterase Sensors for Anti-Alzheimer’s Disease Drug Determination

Electrochemical Acetylcholinesterase Sensors for Anti-Alzheimer’s Disease Drug Determination

Investigation of the Circular Transcriptome in Alzheimer’s Disease Brain

Macrophage migration inhibitor factor (MIF): Potential role in cognitive impairment disorders

Contact Info

Product

Resources

About